Project Grant R01NS139268
Award Date
8/1/24
Completion Date
5/31/29
Dollars Obligated
$679K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), will fund a $705,402 research project to develop a gene therapy treatment for Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a rare genetic metabolic disorder. The project aims to use patient-derived induced pluripotent stem cell (iPSC) neurons and a mouse model to study the efficacy and safety...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded Neurogt Inc. a $1,369,242 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to develop an adeno-associated virus (AAV) gene therapy product for treating Mucopolysaccharidosis (MPS) IIIB. The goal is to further advance this gene therapy towards clinical application and commercialization. In Phase I, the company will optimize large-scale manufacturing of...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, provides $689,689 to Tufts University School of Medicine to develop and test enhanced adeno-associated virus (AAV) vectors that can precisely target specific neuronal populations. The project aims to improve upon current AAV methods by using a hybrid approach combining miniaturized...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders, will fund $419,482 in preclinical testing of a novel gene therapy for a childhood-onset neurodegenerative disease. The award recipient, the University of Texas Southwestern Medical Center, will develop and evaluate a gene therapy product (AAV9-HVAC14OPT) expressing the human VAC14 gene to treat...
This federal Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $1,166,860.00 to the University of Florida's Division of Sponsored Research to develop an AAVtcm8-conAGLU vector for the treatment of Sanfilippo Syndrome Type B.
The project aims to advance the product through Investigational New Drug (IND) approval by conducting necessary...
This $124,246 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) supports the development of advanced CRISPR-based gene editing strategies to correct common ALS-causing mutations in the SOD1 gene. The key objectives are to:
Develop AAV-mediated base editing approaches to correct the SOD1 A5V mutation in vitro.
Develop AAV-mediated...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $699,559 to support the development of a novel adeno-associated viral vector 9 (AAV9) gene therapy for the treatment of neurofibromatosis type 2 (NF2).
The goal of this research is to validate preliminary data and gather additional information on dose-response,...
This $284,331 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop novel methods for characterizing the stability and structure of gene therapy vector genomes in human hepatocytes when challenged by natural viral infections. The two main objectives are:
Tracking changes in adeno-associated virus (AAV) vector genome abundance and episomal configurations in transduced primary human...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $881,675 to Phoenix Nest Inc. to support research and development activities for a gene therapy approach to treat Mucopolysaccharidosis Type IIIC (MPS IIIC), also known as Sanfilippo Syndrome Type C.
The key products and services to be delivered under this 3-year award...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $226,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of Georgia Research Foundation, Inc. to characterize and treat peripheral nervous system dysfunction in Sanfilippo syndrome, a rare genetic disorder also known as mucopolysaccharidosis type IIIA.
The key objectives of this 2-year project include: 1) Developing novel cellular models...